Where to purchase Naxitamab injection

Naxitamab injection (Naxitamab) is a humanized mab that has been approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric (age >1 year) and adult patients with R/R HR-NB in bone and/or bone marrow (BM) who have demonstrated partial response (PR), minor response (MR), or stable disease (SD) after prior treatment.

The U.S. Food and Drug Administration (FDA) approved accelerated approval in November 2020. As a 30-60 minute infusion (standard infusion regimen; SIR) on days 1, 3 and 5 of each cycle (7, 8). This contrasts with treatment regimens for the other approved anti-GD2 monoclonal antibodies (dinutuximab) for HR-NB, which require longer infusion times: dinutuximab administered over 10-20 hours for 4 consecutive days; dinutuximab administered over 8 hours for 5 days, or as a continuous infusion via a portable pump for 10 days. Regarding the type of associated adverse events (AEs) In summary, Nasitumumab Injection is similar to other approved antiGD2 monoclonal antibodies in that most patients receiving Nasitumumab Injection experienced mild to moderate adverse events during therapeutic infusion, including pain, hypotension, hypertension, and bronchospasm. However, many patients also experienced serious adverse events.

It is understood that noxituzumab injection has been approved in China, but it has not yet been included in medical insurance. Its price is still unclear. It is a strictly controlled drug and it is difficult to purchase it. The original drug of Noxetuzumab injection marketed overseas is very expensive, and the price may fluctuate due to the exchange rate. Patients who need to purchase drugs overseas should consult a medical consultant.